Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biotron ( (AU:BIT) ) has shared an update.
Biotron Limited has appointed experienced life sciences executive and board director Dr Paul Kasian as a Non-Executive Director, effective 23 December 2025. With more than three decades of leadership across biotechnology, diagnostics, therapeutics and asset management, including prior roles as chairman or executive chairman at several ASX-listed and private health-related companies and senior investment roles at HSBC, Kasian is expected to strengthen Biotron’s governance, strategic direction and business development capabilities, supporting the company’s growth and positioning within the biotech industry.
More about Biotron
Biotron Limited is an Australian biotechnology company based in Sydney, focused on developing antiviral therapies using its proprietary drug design and development expertise. The company targets significant unmet medical needs in infectious diseases, positioning itself within the broader life sciences and biotech sector and engaging with both domestic and international partners and investors.
YTD Price Performance: -38.89%
Technical Sentiment Signal: Sell
Current Market Cap: A$7.23M
Find detailed analytics on BIT stock on TipRanks’ Stock Analysis page.